Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
US |
|
A
|
Allied Technologies Ltd
SGX:A13
|
SG |
|
K
|
Kinder Morgan Inc
XBER:2KD
|
US |
|
L
|
L'Oreal SA
XETRA:LOR
|
FR |
|
Resaas Services Inc
XTSX:RSS
|
CA |
|
V
|
Vermilion Energy Inc
F:CVZ
|
CA |
|
Fuji Soft Inc
TSE:9749
|
JP |
|
Taka-Q Co Ltd
TSE:8166
|
JP |
|
M
|
Max India Ltd
NSE:MAXIND
|
IN |
|
Astute Metals NL
ASX:ASE
|
AU |
|
Four Corners Property Trust Inc
F:4Z1
|
US |
|
B
|
Bourse Direct SA
SWB:BD6
|
FR |
|
B
|
Bitfarms Ltd
NASDAQ:BITF
|
CA |
|
Earths Energy Ltd
ASX:EE1
|
AU |
|
Y
|
Yangtze Optical Fibre and Cable Joint Stock Ltd Co
OTC:YZOFF
|
CN |
|
J
|
Jhonlin Agro Raya PT Tbk
IDX:JARR
|
ID |
|
Sundram Fasteners Ltd
NSE:SUNDRMFAST
|
IN |
|
Raymond James Financial Inc
NYSE:RJF
|
US |
|
W
|
WICE Logistics PCL
SET:WICE
|
TH |
|
V
|
Vibhavadi Medical Center PCL
SET:VIBHA
|
TH |
|
A
|
Aurelia Metals Ltd
F:YTR
|
AU |
Wall St Price Targets
GLUE Price Targets Summary
Monte Rosa Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GLUE is 29.38 USD with a low forecast of 25.25 USD and a high forecast of 38.85 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GLUE's stock price target?
Price Target
29.38
USD
According to Wall Street analysts, the average 1-year price target for GLUE is 29.38 USD with a low forecast of 25.25 USD and a high forecast of 38.85 USD.
What is the Revenue forecast for Monte Rosa Therapeutics Inc?
Projected CAGR
53%
The compound annual growth rate for Revenue over the next 8 years is 53%.